Core Insights - OrthoPediatrics Corp. reported a 17% year-over-year increase in total revenue for Q1 2025, reaching $52.4 million compared to $44.7 million in Q1 2024 [4] - The company continues to focus on pediatric orthopedics, achieving significant growth in both U.S. and international markets [3][4] Financial Performance - Total revenue for Q1 2025 was $52.4 million, a 17% increase from $44.7 million in Q1 2024 [4] - U.S. revenue increased by 19% to $40.9 million, representing 78% of total revenue, while international revenue grew by 11% to $11.5 million, accounting for 22% of total revenue [4] - Trauma and Deformity revenue rose 14% to $37.9 million, and Scoliosis revenue surged 34% to $13.7 million [5][4] - Gross profit for Q1 2025 was $38.3 million, a 19% increase from $32.2 million in the same period last year, with a gross profit margin of 73% [6] Operating Expenses - Total operating expenses for Q1 2025 were $49.2 million, an 18% increase from $41.9 million in Q1 2024, primarily due to increased personnel and non-cash stock compensation [7][10] - Sales and marketing expenses rose by 17% to $16.6 million, driven by higher sales commissions [8] Profitability Metrics - The net loss for Q1 2025 was $10.7 million, compared to a net loss of $7.8 million in Q1 2024, with a net loss per share of $0.46 [11] - Adjusted EBITDA for Q1 2025 was a loss of $0.4 million, an improvement from a loss of $1.1 million in Q1 2024 [11][29] Cash Flow and Guidance - The company reduced free cash flow usage by 35% compared to the same period last year and anticipates achieving positive free cash flow in Q4 2025 [8] - Full-year 2025 revenue guidance was increased to between $236.0 million and $242.0 million, reflecting a growth of 15% to 18% compared to 2024 [13]